HCC
NAVB

Hirtle Callaghan & Co’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Hirtle Callaghan & Co’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,500
Closed -$40K – 623
2014
Q3 		$40K Hold
1,500
– – 0.01% 329
2014
Q2 		$44K Hold
1,500
– – 0.01% 372
2014
Q1 		$56K Hold
1,500
– – 0.01% 337
2013
Q4 		$62K Hold
1,500
– – 0.01% 309
2013
Q3 		$80K Buy
+1,500
New +$87.4K 0.01% 300

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Hirtle Callaghan & Co's NAVB Position: Q4 2014 in Review

Hirtle Callaghan & Co sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2014, closing a stake of 1,500 shares — an estimated $40K sold.

Hirtle Callaghan & Co first reported a position in NAVB in Q3 2013 and held it in 5 quarters. The position peaked at $80K in Q3 2013. 87 funds tracked by Wall St. Rank hold NAVB as of Q4 2014.

  • Hirtle Callaghan & Co reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2014 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 1,500 Navidea Biopharmaceuticals Inc. shares in Q4 2014, an estimated $40K.
  • Hirtle Callaghan & Co first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2013 and held it in 5 quarters.
  • Hirtle Callaghan & Co's Navidea Biopharmaceuticals Inc. position peaked at $80K in Q3 2013.
  • 87 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2014.

Based on Hirtle Callaghan & Co's 13F filing for Q4 2014, filed 26 Jan 2015.